Hypogonadism

Testosterone Therapy for Hypogonadism May Cut Risk for CV Events

Publish Date July 22, 2021

Risk for myocardial infarction or stroke lower with testosterone therapy among men with hypogonadism and other cardiovascular risk factors

COVID-19 Is Associated With Low Testosterone in Men

Publish Date July 10, 2021

Study reveals that almost 90% of men have hypogonadism at the time of hospital admission for COVID-19.

e-ECE: Testosterone Therapy Mitigates NAFLD in Obese Men With FH, T2D

Publish Date June 16, 2021

Testosterone undecanoate therapy reduces NAFLD grade in obese men with functional hypogonadism and type 2 diabetes

Severe COVID-19 Associated With Low Testosterone in Men

Publish Date May 27, 2021

It is unclear whether low testosterone is a marker or a mediator of severe and impending severe COVID-19 illness.

Inflammatory Diet May Contribute to Testosterone Deficiency in Men

Publish Date April 29, 2021

Each 1 unit increment in Dietary Inflammatory Index was associated with a 4.0% increase in the odds of testosterone deficiency.

Kyzatrex Under Review for Primary and Secondary Male Hypogonadism

Publish Date March 16, 2021

Kyzatrex is an investigational, oral testosterone undecanoate softgel that utilizes lymphatic absorption and phytosterols to increase bioavailability and provide a favorable pharmacokinetic profile.

Kidney Stones Linked With Osteoporosis, Fractures

Publish Date March 10, 2021

Bone loss in patients with kidney stone disease, particularly in men, has been underappreciated in clinical practice, according to investigators.

Testosterone Therapy May Reduce Diabetes Risk

Publish Date January 8, 2021

Additional safety data on testosterone therapy are needed before it can be used to prevent type 2 diabetes.

Nasal Gel Ups Testosterone, Maintains Semen Parameters

Publish Date May 6, 2020

In a study, most symptomatic hypogonadal men treated with Natesto, a short-acting 4.5% nasal testosterone gel, attained normal testosterone levels at 6 months while preserving sperm counts.

Jatenzo, an Oral Testosterone Replacement Therapy, Now Available

Publish Date February 18, 2020

Jatenzo® (testosterone undecanoate; Clarus Therapeutics), an oral testosterone replacement therapy, is now available for the treatment of hypogonadism.